Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment, but further optimization is still direly needed. Here the authors perform a CRISPR screen in CAR T cells to find Cul5 as a negative regulator, with Cul5 deficiency and subsequently enhanced JAK/STAT signaling attributed to improved CAR T efficacy in mouse tumor models.
- Yoshitaka Adachi
- Seitaro Terakura
- Hitoshi Kiyoi
